




**Global
Resource for
Advancing
Cancer
Education**

Program Achievements and Reach

2023 PROGRAM YEAR



Executive Summary

Total Reach in 2023

1,000,000 Website Visits

2,400,000+ Patients and Caregivers Reached



284 Educational Videos Produced

4 Live Webinars

52 Podcasts

GRACE's Program Reach by Tumor Type

- Lung
- Blood
- Pan Tumor
- HPV
- Bladder/GU
- Melanoma
- Head/Neck



GRACE's Global Reach

Lung Cancer Video Library

Reach in 2023



35k+ patients with lung cancer and caregivers

Program Overview

- Long-running patient education video program featuring top oncologists presenting the most current and emerging treatment options
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



13 videos produced in 2023

1. Biomarkers in NSCLC: Understanding Their Importance
2. Changing Treatment in NSCLC: Then and Now
3. What is Liquid Biopsy?
4. Lung Cancer Risk Factors, Histology, and Prior Treatment Options
5. Immunotherapy in Lung Cancer: History and Strategies
6. Immune Checkpoints and PD-L1
7. Benefits and Side Effects of Immunotherapy in Lung Cancer
8. Targeted Therapy in Lung Cancer: The Importance of Biomarkers
9. Side Effects of Targeted Therapy for Lung Cancer
10. Future Directions of Lung Cancer Treatment: Minimal Residual Disease
11. Acquired Resistance in Lung Cancer Treatment
12. Antibody Drug Conjugates and Radiopharmaceuticals: Emerging Therapies for Lung cancer
13. Immunotherapy Future Directions

 <https://cancergrace.org/video-collection/lung-cancer-video-library-english>



Spanish Lung Cancer Video Library

VIDEO BIBLIOTECA ESPAÑOLA DE CÁNCER DE PULMÓN

Reach in 2023



25k+ Spanish speaking patients with lung cancer and caregivers

Program Overview

- Spanish language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Spanish-language videos as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



12 videos produced in 2023

1. Small Cell Versus Non Small Cell Lung Cancer *Cáncer de Pulmón de Células Pequeñas Versus Células no Pequeñas*
2. Lung Cancer Symptoms and Diagnosis *Síntomas y Diagnóstico del Cáncer de Pulmón*
3. Staging Lung Cancer *Estadificación del Cáncer de Pulmón*
4. Facts About Cancer Scans and Biopsies *Datos Sobre las Exploraciones y Biopsias del Cáncer*
5. Small Cell Lung Cancer Treatment *Tratamiento del Cáncer de Pulmón de Células Pequeñas*
6. Non-Small Cell Lung Cancer Treatment *Tratamiento del Cáncer de Pulmón de Células no Pequeñas*
7. Genetic Alterations in Lung Cancer and the Importance of Testing *Alteraciones Genéticas en el Cáncer de Pulmón y la Importancia de las Pruebas*
8. Managing Advanced Non Small Cell Cancer *Manejo del Cáncer de Células no Pequeñas Avanzado*
9. Questions to Ask Your Oncologist *Preguntas para Hacerle a Su Oncólogo*
10. Early and Advanced Stage Cancer Treatment Response *Respuesta al Tratamiento del Cáncer en Estadio Temprano y Avanzado*
11. Recurrent or Metastatic Disease *Enfermedad Recurrente o Metastásica*
12. Palliative and Hospice Care *Cuidados Paliativos y de Hospicio*



<https://cancergrace.org/video-collection/lung-cancer-video-library-spanish>



GRACE

East Asian Lung Cancer Video Library

Reach in 2023



100k+ patients with lung cancer and caregivers who speak East Asian languages

Program Overview

- East Asian language patient education video program featuring top oncologists
- Short, 3-5 minute easy-to-understand Mandarin-language videos with illustrative slides as updates to the searchable online GRACE Lung Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



22 videos produced in 2023

1. KOREAN; Lung Cancer in Korea: Current Statistics and Risk Factors 한국의 폐암: 현재 통계 및 위험 요소
2. KOREAN: Types of Lung Cancer: Small Cell Versus Non Small Cell 폐암 유형: 소세포폐암 대 비소세포폐암
3. KOREAN: Lung Cancer Treatment: Factors to Consider 폐암 치료: 고려해야 할 요소
4. KOREAN: Lung Cancer Treatment Options 폐암 치료 옵션
5. KOREAN: Targeted Therapy in Lung Cancer 폐암에서의 표적 치료
6. KOREAN: EGFR-Mutated Lung Cancer Treatment EGFR 돌연변이 폐암 치료
7. KOREAN: Immunotherapy in Lung Cancer Treatment 폐암 치료에서의 면역요법
8. KOREAN: Pembrolizumab in Advanced Lung Cancer 진행된 폐암에서의 펌브로리주맙
9. KOREAN: The Importance of Lung Cancer Screening 폐암 검진의 중요성
10. JAPANESE: Biomarkers in NSCLC: Understanding Their Importance 非小細胞肺癌におけるバイオマーカー : その重要性を理解する
11. JAPANESE: Changing Treatment in NSCLC: Then and Now 非小細胞肺癌における治療の変化 : 過去と現在
12. JAPANESE: What is Liquid Biopsy? 液体生検とは何ですか?
13. MANDARIN: Lung Cancer Risk Factors, Histology, and Prior Treatment Options 肺癌的风险因素、组织学和先前的治疗选择
14. MANDARIN: Immunotherapy in Lung Cancer: History and Strategies 肺癌中的免疫疗法 : 历史与策略
15. MANDARIN: Immune Checkpoints and PD-L1 免疫检查点和PD-L1
16. MANDARIN: Benefits and Side Effects of Immunotherapy in Lung Cancer 肺癌免疫疗法的好处和副作用
17. MANDARIN: Targeted Therapy in Lung Cancer: The Importance of Biomarkers 肺癌靶向治疗 : 生物标志物的重要性



<https://cancergrace.org/video-collection/east-asian-lung-cancer-video-library>



GRACE

East Asian Lung Cancer Video Library

18. MANDARIN: Side Effects of Targeted Therapy for Lung Cancer 肺癌靶向治疗的副作用
19. MANDARIN: Future Directions of Lung Cancer Treatment: Minimal Residual Disease 肺癌治疗的未来方向：极小残余疾病
20. MANDARIN: Acquired Resistance in Lung Cancer Treatment 肺癌治疗中的获得性耐药
21. MANDARIN: Antibody Drug Conjugates and Radiopharmaceuticals: Emerging Therapies for Lung cancer 抗体药物结合物和放射性药物：肺癌新兴疗法
22. MANDARIN: Immunotherapy Future Directions 免疫治疗的未来方向

 <https://cancergrace.org/video-collection/east-asian-lung-cancer-video-library>

Leading Development and Current Questions in Lung Cancer

Reach in 2023



10k+ lung cancer patients

Program Overview

- Patient education video program featuring top oncologists discussing the latest current and emerging lung cancer updates direct from ASCO in a roundtable discussion format
- Short, 3-5 minute easy-to-understand videos filmed directly following ASCO
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



11 videos produced in 2023

1. The FANSS Study: The Importance of Lung Cancer
2. The ADAURA Trial: Tagrisso for Patients with Resected/Resectable EGFR+ NSCLC
3. The ADAURA Trial: Flaws and Results
4. Keynote 671: Perioperative Keytruda for Early Stage NSCLC
5. Adjuvant Immunotherapy: Questions and Concerns
6. Treatment Options for Patients with Advanced NSCLC
7. Tumor Treating Fields for Lung Cancer
8. Sunvozertinib for Patients with EGFR Exon 20 Insertion NSCLC
9. Treatment Options for Patients with EGFR+ NSCLC and Acquired Resistance
10. Emerging Treatment Options for Small Cell Lung Cancer (SCLC): Adding a PARP Inhibitor
11. Chemotherapy +/- Immunotherapy for Mesothelioma

 <https://cancergrace.org/video-collection/asco-lung-roundtable>



GRACE

Lung Cancer Case Based Panel Discussions

Reach in 2023



15k+ lung cancer patients reached

Program Overview

- Patient education video program featuring a panel of 3-5 leading oncologists presented with lung cancer specific cases highlighting discussion where the video audience is a “fly on the wall” as panelists brainstorm the best approaches to each case in a casual, non-lecture setting
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



10+ videos in production

The following topics were subjects of video content for the 2023 program year (videos are still in final production/editing at the time of this report)

1. Clinical Stage 2 Lung Adenocarcinoma: Biomarkers and Treatment Approaches
2. Stage 3A Node-Positive Lung Adenocarcinoma with ALK Rearrangement
3. Non-Bulky NSCLC 2B Disease: The Role of Chemoimmunotherapy
4. EGFR Mutated Adenocarcinoma
5. Stage 3 Squamous Lung Cancer with Low PD-L1

 <https://cancergrace.org/video-collection/case-based-panel-discussions>



Targeted Therapies Patient Forum

A LIVE VIRTUAL INTERACTIVE PATIENT EDUCATION EVENT

Reach in 2023



5k+ views/attendees estimated through 12/31/23 with content available as enduring material for 1 year. Estimating 15k+ views of content in the first 12 months.

Program Overview

- 1/2 day live virtual event featuring top oncologists discussing current and emerging information with live audience
- Break out sessions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment



Live virtual event was held on July 15, 2023 virtually. Hundreds of real-time attendees from around the world viewed the program live and had the opportunity to interact with and participate in a live Q&A with the panels.

The event was video recorded, and segments were published as enduring material, resulting in 85 videos produced featuring topics of the panel discussions as follows:

1. Biomarkers in NSCLC
2. The Importance of Biomarker Testing: What is Liquid Biopsy?
3. Current Recommendations and Best Practices for Biomarker Testing
4. Barriers to Biomarker Testing: Ordering Tests
5. Barriers to Biomarker Testing: Cost and Insurance
6. Biomarker Driven Therapy for NSCLC
7. The Adaura Trial: The Effect on EGFR+ Treatment
8. Key Points from the Adaura Trial: Osimertinib
9. The Alina Trial for ALK+ NSCLC
10. Neoadjuvant Treatment for Patients with NSCLC
11. Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
12. Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
13. Treatment Options for Patients with Locally Advanced Unresectable NSCLC

 <https://cancergrace.org/video-collection/targeted-therapies-patient-forum-english>



Targeted Therapies Patient Forum

A LIVE VIRTUAL INTERACTIVE PATIENT EDUCATION EVENT

14. The Role of the Patient as Advocate
15. Adding to Targeted Therapy: Current Statistics and Biology
16. Local Therapy for Limited Metastatic NSCLC
17. Local Therapy for Patients After Frontline Therapy
18. Local Therapy for Patients with Oligoprogressive NSCLC
19. The Future of Local Therapy
20. Q&A: Can a Patient Receive SBRT if Unable to Hold Their Breath?
21. Q&A: Does Radiation Increase Toxicity for Patients on Targeted Therapy?
22. Q&A: What Targeted Therapy Options Exist for Patients with Driver Mutations?
23. Q&A: Is Biomarker Testing Common in Early Stage NSCLC?
24. Q&A: Are There Ongoing Trials for Rare NSCLC Mutations?
25. Q&A: Should Biomarker Testing Be Performed on Patients with Squamous Cell Lung Cancer?
26. Q&A: Resistance on Targeted Therapy: What Questions Should a Patient Ask Their Doctor?
27. Q&A: What Are Some Local Therapy Options for Patients with NSCLC?
28. Q&A: What Can Patients Do to Close the Biomarker Testing Gap?
29. Q&A: What Do We Know About Prevention and Causes of Lung Cancer?
30. Q&A: What Are the Platform Options for SBRT?
31. Q&A: Why Can Some Patients Remain on TKIs Without Acquiring Resistance?
32. Q&A: Should a Patient with High PD-L1 Wait for Genetic Testing Results Before Starting Treatment?
33. Treatment Options and Study Data for Patients with ALK+ NSCLC
34. Treatment Options and Study Data for Patients with ROS1+ NSCLC
35. Rare Fusions in NSCLC: RET
36. RET Fusion Treatment: Selpercatinib
37. RET Fusion Treatment: Pralsetinib
38. Safety and Toxicity of Selpercatinib Versus Pralsetinib
39. The Future of RET+ NSCLC Treatment
40. NTRK+ NSCLC: Treatment Options and Side Effects
41. NRG1 Fusions: Treatment Options
42. Q&A: Is RNA Testing Available Commercially?
43. Q&A: Can Patients Use Off-Label Treatment Options for ROS1+ NSCLC?
44. Q&A: How Effective is Cabozantinib for ROS1 After Progression on Crizotinib?
45. Q&A: Is Alectinib an Option for Patients with DCTN1 ALK+ Disease?
46. Q&A: Should a Patient with New Lesions Switch from Alectinib to Lorlatinib?
47. Q&A: Can Pemetrexed and Bevacizumab be used for Squamous Disease?
48. Q&A: TKI Neoadjuvant Studies: Is Complete Pathological Response Possible?
49. Q&A: When Should a Patient Do Biomarker Retesting?
50. Q&A: Which First Line TKI Should Be Used for a Patient with Stage IV Disease and No Brain Mets?
51. Q&A: Does BRAF in Non-Smokers Respond to Immunotherapy?
52. Q&A: RET Fusion, Lobectomy, and Chemo: Risk of Recurrence?
53. EGFR Mutations in Advanced NSCLC
54. Combination Therapy with Osimertinib for EGFR+ NSCLC
55. Resistance Mechanisms in EGFR+ NSCLC Treatment

 <https://cancergrace.org/video-collection/targeted-therapies-patient-forum-english>



Targeted Therapies Patient Forum

A LIVE VIRTUAL INTERACTIVE PATIENT EDUCATION EVENT

56. Post-Osimertinib Treatment Options for EGFR+ NSCLC
57. The ADAURA Trial: 2023 Updates
58. Neoadjuvant Osimertinib for Patients with Surgically Resectable EGFR+ NSCLC
59. Metastatic EGFR+ NSCLC: Recent Developments
60. KRAS+ NSCLC: Details and Diagnosis
61. Challenges of Targeted KRAS Treatment and Current Treatment Options
62. Barriers to Drug Development for KRAS G12C+ NSCLC
63. KRAS G12C Inhibitors Versus Chemotherapy in Second Line: Current Studies
64. Krystal 7 Study: Adagrasib +/- Pembrolizumab for KRAS G12C+ NSCLC
65. Q&A: How Do Oncologists Approach Compound EGFR Mutations?
66. Q&A: What do Oncologists do for Patients with Co-Alterations?
67. Q&A: What are Treatment Options for Patients with Leptomeningeal Disease?
68. Q&A: What is the Efficacy of Amivantamab and Lazertinib?
70. Q&A: Would a Patient with KRAS+ NSCLC and No Smoking History Benefit from Immunotherapy?
71. Q&A: What Should Patients Know About Liver Toxicity in Treatment?
72. An Introduction to Advocacy
73. Advocacy Resources and Organizations to Know
74. EGFR Resisters: An Advocacy Group
75. Decreased Cancer Mortality: How Treatments Have Improved
76. Living with Advanced Cancer: Handling Uncertainty
77. What is Palliative Care?
78. The Goal of Palliative Care
79. Q&A: Where Should Investments Be Made to Benefit Patients?
80. Q&A: How Can We Close the Gap in Clinical Trials?
81. Q&A: How Can Oncologists Integrate Patient Advocates into Clinical Studies?
82. Q&A: What Can be Done for Lung Cancer Prevention Advocacy?
83. Q&A: What are the Differences in Palliative and Hospice Care?
84. Q&A: Am I Increasing my Lung Cancer Risk with Campfires?
85. Q&A: How Do I Integrate Palliative Care Services?
86. Q&A: How do I Handle Side Effects?

 <https://cancergrace.org/video-collection/targeted-therapies-patient-forum-english>



Terapias Dirigidas en Español Foro de Pacientes

SPANISH TARGETED THERAPIES PATIENT FORUM

Reach in 2023



5k+ views/attendees estimated through 12/31/22 with content available as enduring material for 1 year. Estimating **10k+** views of content in the first 12 months.

Program Overview

- 2.5 hour live event featuring top oncologists from the US, Columbia and Costa Rica discussing current and emerging information with live audience
- Panel discussions address rare mutations and targeted information
- Interactive program includes live audience and Q&A sessions
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment



Live event was held on August 12, 2023 virtually using Zoom Webinar. Hundreds of ‘real-time’ attendees from around the world viewed the program and had the opportunity to interact with and participate in a live Q&A with the panels.

The event was video recorded, and segments were published as enduring material, resulting in 43 videos produced featuring topics of the panel discussions as follows:

1. Panel de Discusión: Opciones de Tratamiento para la Enfermedad Metastásica de EGFR+
2. Panel de Discusión: Causas de Cambios en los Laboratorios y en el Regimiento de Medicamentos
3. Panel de Discusión: ¿Por Qué Regresó el Tumor?
4. Panel de Discusión: Cambios en la Medicación e Importancia de las Pruebas Genéticas
5. Panel de Discusión: Opciones de Tratamiento para Pacientes con NSCLC EGFR G12C
6. Panel de Discusión: Opciones para el Dolor de Cabeza y Próximos Pasos
7. Panel de Discusión: Lesiones Cerebrales en Pacientes con NSCLC
8. Panel de Discusión: El Futuro del Tratamiento del NSCLC y el Acceso a los Medicamentos en América Latina
9. Qué es KRAS: Subtipos en NSCLC
10. Tipos de KRAS e Historial de Tratamiento



<https://cancergrace.org/video-collection/targeted-therapies-patient-forum-spanish>



GRACE

Terapias Dirigidas en Español Foro de Pacientes

SPANISH TARGETED THERAPIES PATIENT FORUM

11. Opción de Tratamiento KRAS: Sotorasib
12. Opción de Tratamiento KRAS: Adagrasib
13. Terapia Combinada y Co-Mutaciones en KRAS
14. Ensayos Clínicos de KRAS y Futuro del Tratamiento
15. Diagnóstico Personalizado: Cómo ha Cambiado el Tratamiento
16. Alteraciones Genómicas y Pruebas de Biomarcadores
17. PD-L1: Por Qué es Importante
17. Carga Mutacional Tumoral (TMB) y Su Papel en el Tratamiento
18. Estado Comutacional y PD-L1
19. Biopsia Líquida y Oncología de Precisión
20. Elección de Tratamientos de Primera Línea para el NSCLC
21. Resistencia: Utilización de Biopsia Líquida para Decidir la Opción de Segunda Línea
22. Evaluación de la Respuesta en el NSCLC Metastásico
23. Detección de Enfermedad Residual Mínima (ERM) Después del Tratamiento
24. Detección Temprana de NSCLC con Biopsia Líquida
25. Uso de Terapia Dirigida en Enfermedades en Etapas más Tempranas
26. Datos de Prueba: Adaura
27. Osimertinib Adyuvante para Pacientes con Enfermedad en Estadio 1B/2/3A
28. Críticas de Adaura y Próximos Pasos
29. Datos de Prueba: Impower 010, Checkmate 816 y Keynote 671
30. La Importancia de la Detección del Cáncer de Pulmón y las Pruebas de Biomarcadores
31. Q&A: ¿Existen Indicadores de que un Paciente Desarrollará Resistencia?
32. Q&A: ¿Cuáles son los Próximos Pasos Después de la Progresión con Osimertinib?
33. Q&A: ¿Las Zonas Rurales Ofrecen Biopsia Líquida?
34. Q&A: ¿Es Posible Tener Más de un Biomarcador?
35. Q&A: ¿Cuál es la Diferencia Entre los Inhibidores de MEK y ERK?
36. Q&A: ¿Cuál es el Más Efectivo: Pembrolizumab, Nivolumab o Atezolizumab?
37. Q&A: ¿Mi Mutación Determina el Éxito de Mi Terapia Dirigida?
38. Q&A: ¿Es Eficaz la Terapia Dirigida en Enfermedades Avanzadas?
39. Q&A: ¿Puedo Volver a un Tratamiento Anterior?
40. Q&A: ¿Cuánto Tiempo Lleva Saber Si la Terapia Dirigida Está Funcionando?
41. Q&A: ¿Algunas Mutaciones Responden Mejor que Otros?
42. Q&A: ¿Son los Ensayos Clínicos el Último recurso?

 <https://cancergrace.org/video-collection/targeted-therapies-patient-forum-spanish>

Lung Cancer ONCTALK

LIVE ONLINE: INTERACTIVE PATIENT EDUCATION EVENT

Reach in 2023



15k+ lung cancer patients reached

Program Overview

- Live streamed webinar program featuring a panel of top oncologists
- Interactive program includes live streamed real-time audience; includes a Q&A session
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



Live event was held on February 10, 2024, virtually using Zoom Webinar. Hundreds of 'real-time' attendees had the opportunity to interact with and participate in a live Q&A with the panels.

The event was video recorded, and segments were published as enduring material, resulting in 50 videos produced featuring topics of the panel discussions as follows:

1. Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC
2. AEGEAN Trial: Perioperative Durvalumab for NSCLC
3. Keynote 671: Perioperative Pembrolizumab for NSCLC
4. NEOTORCH Trial: Perioperative Toripalimab for NSCLC
5. Checkmate 77T: Perioperative Nivolumab in NSCLC
6. IMPower 010: Adjuvant Atezolizumab in NSCLC
7. Keynote 091: Adjuvant Pembrolizumab
8. Remaining Questions and Controversies in the NSCLC Study Space
9. Circulating Tumor DNA (ctDNA) and Overtreatment in NSCLC
10. Lung Resection in Early Stage NSCLC: An Overview
11. Wedge Resection for Early Stage NSCLC
12. Segmentectomy for Early Stage NSCLC
13. Lobectomy for Early Stage NSCLC
14. Lymph Node Dissection in Early Stage NSCLC
15. Lobar Versus Sublobar Resection in NSCLC
16. Minimally Invasive Lung Resection: VATS and RATS
17. Postoperative Course: What To Expect After Early Stage NSCLC Surgery
18. Neoadjuvant, Perioperative, Adjuvant: Defining Terms and Advantages
19. Staging Disease: How Oncologists Stage NSCLC
20. Biomarkers in NSCLC

 <https://cancergrace.org/video-collection/lung-onctalk>



Lung Cancer ONCTALK

LIVE ONLINE: INTERACTIVE PATIENT EDUCATION EVENT

21. Perioperative Versus Preoperative Surgery in NSCLC
22. Pneumonectomy in NSCLC
23. Q&A: Will All Trials Result in Therapeutic Changes?
24. Antibody Drug Conjugates: What Are Antibodies?
25. What Are Antibody Drug Conjugates?
26. Toxicities in Antibody Drug Conjugate Treatment
27. Antibody Drug Conjugate Treatment in Lung Cancer
28. Bispecific Antibodies in Lung Cancer
29. Bispecific Antibodies: Amivantamab
30. Using Radiation Therapy in Metastatic Lung Cancer: An Overview
31. Advances in Oligometastatic Disease
32. Maintenance Systemic Therapy: The NRG-LU Trial
33. Stereotactic Body Radiotherapy (SBRT) for Oligoprogressive NSCLC
34. Future Goals of Metastatic NSCLC Treatment
35. Q&A: How Do Oncologists Determine Oligoprogressive Status?
36. Q&A: How Can We Learn from Unsuccessful Studies?
37. Q&A: What Are Next Steps in Antibody Drug Conjugates?
38. Q&A: What Are Toxicities in Bispecific Antibody Treatments?
39. Q&A: Should We Use Focal Therapy or Whole Brain Therapy for Brain Metastases?
40. Q&A: Do Advanced Stage Patients in Trials Only Receive a Placebo?
41. Q&A: Are There Health Conditions That Impact Surgical Options in Cancer?
42. Q&A: What Is the Average Length of Radiation Treatment for Patients with Stage IV Disease?
43. Q&A: Can Gamma Knife Radiosurgery Be Used for C3 Metastases?
44. Q&A: How Do Oncologists Determine Which Patients Receive Radiotherapy?
45. Q&A: What Does Monitoring Look Like After Adjuvant Chemotherapy?
46. Q&A: What Does Lung Cancer Surgical Recovery Look Like?
47. Q&A: What Are Costs and Side Effects of Antibody Drug Conjugates?
48. Q&A: Are All Metastases Treatable with Radiation, and How Is Success Measured?
49. Q&A: Are There Specific Lifestyle Changes Patients Can Make During Treatment?
50. Q&A: Are There Resources for Connection With Support Groups or Counseling Services?

 <https://cancergrace.org/video-collection/lung-onctalk>



GRACE

Bladder Cancer Video Library

Reach in 2023



10k+ patients with bladder cancer and caregivers reached

Program Overview

- Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online bladder cancer video library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



10+ videos in production

The following topics were subjects of video content for the 2023 program year (videos are still in final production/editing at the time of this report)

1. PD-L1 in Metastatic Bladder Cancer
2. Tumor Mutation Burden and Neoantigens
3. Tumor Infiltrating Lymphocytes and Tumor Associated Macrophages
4. Microbiomes and Genomics: The Effect on Immunotherapy
5. Circulating Tumor DNA
6. Artificial Neural Networks in Bladder Cancer Treatment
7. Systemic Therapy and Neoadjuvant Treatment
8. Bladder Cancer Staging
9. Cisplatin Usage in Bladder Cancer
10. Neoadjuvant Chemotherapy
11. Adjuvant Versus Neoadjuvant Immunotherapy
12. Neoadjuvant Systemic Therapy
13. Neoadjuvant Immunotherapy for Cisplatin-Ineligible Patients

 <https://cancergrace.org/video-collection/bladder-cancer-video-library>



Melanoma Video Library

Reach in 2023



10k+ patients and caregivers reached

Program Overview

- Patient Video program featuring leading oncologists providing short, 3-5 minute topic-specific video updates for our searchable online melanoma video library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



10+ videos in production

The following topics were subjects of video content for the 2023 program year (videos are still in final production/editing at the time of this report)

1. Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma
2. Treatment Options for Metastatic Melanoma
3. The Role of Neoadjuvant Treatment in Melanoma Care
4. The Importance of Screening for Skin Cancers
5. Molecular Profiling and Driver Mutations in Melanoma Treatment
6. Adjuvant Treatment Options for Melanoma
7. Leptomeningeal Disease/ Brain Mets in Melanoma

 <https://cancergrace.org/video-collection/melanoma-video-library>



Leading Developments and Current Questions in Head & Neck Cancer

Reach in 2023



5k+ head and neck cancer patients reached

Program Overview

- Patient education video program featuring top oncologists discussing the latest current and emerging head and neck cancer updates direct from ASCO in a roundtable discussion format
- Short, 3-5 minute easy-to-understand videos filmed directly following ASCO
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



5 videos produced in 2023

1. Curable HPV Positive Head and Neck
2. Curable HPV Negative Head and Neck Cancer
3. Incurable HPV Negative Head and Neck Cancer
4. Recurrent/Metastatic HPV Positive Head and Neck Cancer
5. Advances in Thyroid Cancer Treatment



<https://cancergrace.org/video-collection/asco-head-and-neck-cancer-news-and-updates>



Human Papilloma Virus (HPV) Advances

Reach in 2023



35k+ patients and caregivers reached

Program Overview

- Patient education video program featuring top oncologists presenting the most current and emerging information about vaccinations, testing and therapy related to HPV
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



10+ videos in production

The following topics were subjects of video content for the 2023 program year (videos are still in final production/editing at the time of this report)

1. HPV Advances: Deintensification in HPV-Driven SCCHN
2. Reduction of Postoperative Adjuvant Intensity
3. Benefits of Induction Chemotherapy
4. Deintensification: Is It the Standard of Care?
5. Two Main Causes of Head and Neck Cancer
6. Prevention of HPV-Related Head and Neck Cancer
7. Current Head and Neck Cancer Treatments
8. De-Escalation: Radiation Dose and Field
9. Induction Chemotherapy
10. Guiding Post-Operative Radiation by Surgery
11. Identifying Candidates for De-Escalation

 <https://cancergrace.org/video-collection/hpv-advances-patient-education-program>



GRACE

Testing and Early Diagnosis

Reach in 2023



35k+ patients and caregivers

Program Overview

- Patient education video program featuring top oncologists presenting the most current and emerging information about the importance of testing before and after diagnosis or at recurrence/progression
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



8 videos produced in 2023

1. Prevention and Early Diagnosis in Skin Cancer
2. Lung Cancer Screening: A Patient Perspective
3. Early Diagnosis of Breast Cancer: Importance and Statistics
4. Breast Cancer Screening Recommendations
5. Breast Cancer Screening Risks
6. Identifying Individuals at Higher Risk of Breast Cancer
7. Breast Cancer Risk Factors
8. Lowering Your Breast Cancer Risk

 <https://cancergrace.org/video-collection/testing-and-early-diagnosis>



Blood Cancer Video Library

Reach in 2023



35k+ patients with blood cancer and caregivers reached

Program Overview

- Patient education video program featuring top oncologists presenting the most current and emerging treatment options
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



10+ videos in production

The following topics were subjects of video content for the 2023 program year (videos are still in final production/editing at the time of this report)

1. New Treatments For Diffuse large B-Cell Lymphoma and Follicular Lymphoma: Bispecific Antibody Therapy
2. CLL (Chronic Lymphocytic Leukemia) -- A New Generation of BTK Inhibitors
3. Mantle Cell Lymphoma - Exciting Outcomes for CAR-T Cell Therapy Trials
4. The Prevalence and Epidemiology of Blood Cancers
5. Diagnosis and Management of Blood Cancers
6. Management of Treatment of Blood Cancers - Bone Marrow Transplantation & Other Therapies
7. Cancer Care in HIV-Infected Patients
8. Cancer Care in Senior Patients
9. Closing the Gap in Cancer Care for Ethnic Minorities
10. Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: CAR-T Cells
11. Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: Bispecific Antibodies
12. Treatment Options for Relapsed Diffuse Large B-Cell Lymphoma
13. CAR T-Cell Therapy for Patients with Relapsed Diffuse Large B-Cell Lymphoma
14. CAR T-Cell Therapy Side Effects
15. Emerging Types of CAR T-Cell Therapy

 <https://cancergrace.org/video-collection/blood-cancer-video-library>



ONCTALK Blood Cancer

A LIVE VIRTUAL INTERACTIVE PATIENT EDUCATION EVENT

Reach in 2023



15k+ patients with blood cancers

Program Overview

- Live streamed webinar program featuring a panel of top oncologists
- Interactive program includes live streamed real-time audience; includes a Q&A session
- Recorded event is published online as enduring material
- Videos of the recorded event are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



Live event was held on September 23, 2023, virtually using Zoom Webinar. Hundreds of 'real-time' attendees had the opportunity to interact with and participate in a live Q&A with the panels.

The event was video recorded, and segments were published as enduring material, resulting in 42 videos produced featuring topics of the panel discussions as follows:

1. Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab
2. Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab
3. Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
4. Bispecifics for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
5. Mosunetuzumab for Follicular Lymphoma
6. What is a Bone Marrow Transplant?
7. Autologous Bone Marrow Transplants: Use in Myeloma and Lymphoma
8. Transplants in Myeloma and Lymphoma: Effects on Survival
9. Immunotherapy in Multiple Myeloma: An Overview
10. Bispecific Antibodies in Myeloma: Approvals and Clinical Trials
11. Types of Bispecific Antibodies
12. Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
13. Pros and Cons of Bispecific Antibodies
14. Management of Bispecific Antibodies Side Effects
15. Patient Role in Bispecific Antibody Treatment

 <https://cancergrace.org/post/view-full-blood-cancer-onctalk>



GRACE

ONCTALK Blood Cancer

A LIVE VIRTUAL INTERACTIVE PATIENT EDUCATION EVENT

16. The Future of Bispecific Antibodies
17. What is Smoldering Multiple Myeloma?
18. Identifying Smoldering Multiple Myeloma Patients: Risk Factors
19. Approaching Treatment for Smoldering Multiple Myeloma
20. Clinical Trials in Patients with High Risk or Smoldering Multiple Myeloma
21. Phase II Clinical Trials for Intermediate to High Risk Smoldering Multiple Myeloma
22. Curative Strategies for Patients with Smoldering Multiple Myeloma
23. Dietary Changes for Patients with Smoldering Multiple Myeloma
24. Q&A: Should a Young Patient with Standard Risk Myeloma Always Have an Autologous Transplant?
25. Q&A: If a Patient has Exhausted Standard Therapies, Should They Utilize CAR T-Cell or Bispecifics?
26. Q&A: Is Multiple Myeloma a Myelogenous Cancer?
27. Q&A: Do Bispecifics Cure Diffuse Large B-Cell Lymphoma?
28. Q&A: Do Oncologists Recommend Treatment for Patients with Smoldering Myeloma?
29. Q&A: Is There a Correlation Between Elevated Von Willebrand Factor and Smoldering Myeloma?
30. Q&A: Is my Clinical Trial Affecting my Body's Reaction to the Covid-19 Vaccine?
31. Q&A: What are the Next Steps for a Patient with Myeloma Who Has First Relapse After Transplant?
32. Q&A: Should I Change my Myeloma Treatment if I Feel Healthy?
33. Q&A: What is the Difference Between Biochemical Relapse and Clinical Relapse?
34. Q&A: How Successful are Bone Marrow Transplants for Lymphoma?
35. Q&A: Does Bispecific Treatment for Lymphoma Affect Fertility?
36. Q&A: Are There Financial or Location Limitations to Bispecific Antibody Treatments?
37. Q&A: How Do Oncologists Determine Treatment Order?
38. Q&A: Are Veterans at Higher Risk of Blood Cancer?
39. Q&A: What is the Difference in Autologous vs. Allogeneic Transplant in Myeloma?
40. Q&A: What is the Most Important Thing to Discuss with my Doctor Regarding Bispecific Treatment in Lymphoma?
41. Q&A: How Can I Reduce my Risk of Cytokine Release Syndrome (CRS)?
42. Q&A: Do People in Rural Communities Have Equal Access to Treatment Options?

 <https://cancergrace.org/post/view-full-blood-cancer-onctalk>



Clinical Trials Experience Through Storytelling

Reach in 2023



5k+ Patients with cancer and caregivers

Program Overview

- Patient advocates create new content for the GRACE video library based on their clinical trials journey
- Content is presented through storytelling as an educational tool for patients considering a clinical trial
- Short, 3-5 minute easy-to-understand videos as updates to the searchable online GRACE Cancer Video Library
- Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



Videos and articles produced in 2023

1. Immune Related Adverse Events (IRAE):

- a) Misdiagnosis
- b) Checkpoint inhibitors
- c) No specialists for IRAE - first IRAE Clinic

2. Family/Caregivers and Clinical Trials

- a) Misconceptions
- b) Mental and emotional toll on caregivers
- c) Self-advocacy; cancer community importance

3. Access to Clinical Trials

- a) Preventive care baseline
- b) Need for more diversity in clinical trials
- c) Fear of experimenting; misconceptions

4. Racial Disparities in Clinical Trials:

- a) Genomics
- b) Health Equity
- c) The importance of representation



<https://cancergrace.org/video-collection/clinical-trials-through-storytelling>



GRACE Patient Education Ambassador Program

Reach in 2023



15k+ patients with cancer and caregivers reached

Program Overview

- Fellows and finishing Fellows are recruited to expand and create new content for the GRACE patient education library based on their specialty.
- A portion of this program focuses on communication strategies as they enter their practice.
- Content is created in audio (podcast), written and video formats. Videos are transcribed so patients may print them and take them to their health care provider appointment

2023 Program Details/Achievements



Varied content produced by oncology fellows

The 2023 program year for the Patient Education Ambassadors program runs from July 1, 2023 - June 30, 2024. Highlights of this program's past patient education content, and planned content, include:

- 1. 2019-2020 program year: 2 Fellows selected and content produced:**
 - a) Dr. Arjun Gupta: Supportive Care
 - b) Dr. Narjust Duma: Latino and minority concerns, myths and advocacy
- 2. 2020-2021 program year: 4 Fellows selected and content produced:**
 - a) Dr. Ana Manana Velazquez: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Idalid Franco as well as content about radiation oncology
 - b) Dr. Abdul Rafeh Naqash: Clinical trials education and minority reach)
 - c) Dr. Idalid Franco: Latino and minority concerns and advocacy regarding COVID-19 with Dr. Ana Manana Velazquez as well as content about radiation oncology)
 - d) Dr. Medhavi Gupta: Healthcare disparities; breast cancer)
- 3. 2021-2022 program year: 4 Fellows selected and content produced:**
 - a) Dr. Aakash Desai: health disparities and infographics for patients in India and Nepal
 - b) Dr. Daniel Kwon: Prostate cancer and decision aids
 - c) Dr. Edina Wang: Chinese health literacy and radiation oncology
 - d) Dr. Eric Singhi: Misinformation mitigation and reaching medically underserved

 <https://cancergrace.org/video-collection/patient-education-ambassador-program>



GRACE Patient Education Ambassador Program

4. 2022-2023 program year: 4 Fellows selected. Content to be produced in early 2023

- a) Dr. Ashish Gupta: First steps after diagnosis, GI treatments
- b) Dr. Mazie Tsang: Decision making tools, geriatric lymphoma patient education
- c) Dr. Sridevi Rajeeve: CAR T-Cell patient education, lymphoma and myeloma patient education
- d) Dr. Fernando Diaz: Patient education for latino patient community, first steps after diagnosis

5. 2023-2024 program year: 7 Fellows selected. Content to be produced in early 2024

- a) Dr. Kaitlin Kyi: Advance Directives
- b) Dr. Gladys Rodriguez: Gastrointestinal malignancies
- c) Dr. Ivy Riano: Spanish language content – immunotherapy, PD1 expression, side effects, Clinical Trials 101
- d) Dr. Matthew Kurian: Genetics 101, Prostate Cancer – diagnosis to care
- e) Dr. Jacob Adashek: Genetics 101
- f) Meera Ragavan: Financial Toxicity, Clinical Trials 101, Palliative care
- g) Dr. Karan Jatwani: Prostate Cancer – diagnosis to care, Palliative care

 <https://cancergrace.org/video-collection/patient-education-ambassador-program>



GRACE Podcasts

Reach in 2023

This program publishes one podcast each week. Listener metrics of **500** for each podcast released and published online for future listening was anticipated within 1 year of each podcast release, totaling over **25k** 'listens' to the 2023 podcast program.

Program Overview

- Podcast program covering the most current and emerging treatment options which supports the content in the other GRACE programs such as lung cancer, blood cancers, and bladder cancer via an alternate delivery method and additional content
- Features leading oncologists in each 5-20 minute episode
- One episode will be published per week for 52 weeks designed to help patients by providing an innovative access point
- Program supports other GRACE programs by offering access to patient education in an alternative method, allowing patients to watch videos, read articles, and now listen to this educational information while driving, cooking, etc. This will greatly broaden our patient reach.

2023 Program Details/Achievements



Weekly podcast produced and published all **52 weeks** in 2023

 <https://cancergrace.org/grace-podcasts>



GRACE Online Forum

Reach/Metrics



GRACE website receives over **1,000,000** visitors each year



The GRACE Online Forum is one of the main features of our website and is moderated by GRACE staff



Online Forum receives thousands of new topic threads each year, creating a hub of information on our website

 <https://cancergrace.org/forums>



GRACENotes Newsletter

Reach/Metrics



GRACE's newsletter, GRACENotes, reaches over **1,000,000** patients each year through direct distribution and online publishing

Newsletter Features

1. New program information
2. Links to threads on Online Forum
3. Valuable, concise resource for patients to drill down to educational content and stay abreast of new content we are publishing throughout the year



GRACE'S 2023 Global Reach

232,783 Patients/Caregivers in 133 Countries Reached (increase of 30% reach from 2022)
(Outside of the United States)

Country	#
Albania	109
Algeria	90
Andorra	4
Antigua & Barbuda	8
Argentina	118
Armenia	50
Australia	9,862
Austria	375
Azerbaijan	33
Bahamas	41
Bahrain	64
Bangladesh	392
Barbados	36
Belarus	93
Belgium	1,023
Belize	16
Benin	4
Bermuda	11
Bhutan	8
Bosnia & Herzegovina	343
Brazil	599
Brunei	27
Bulgaria	328
Cambodia	31
Cameroon	9
Canada	13,808
Cayman Islands	4
Chile	207
China	101,609
Colombia	940
Costa Rica	269
Côte d'Ivoire	17

Country	#
Croatia	840
Cuba	10
Curacao	4
Cyprus	297
Czechia	109
Denmark	275
Dominican Republic	106
Ecuador	61
Egypt	535
El Salvador	1,822
Estonia	85
Ethiopia	43
Fiji	7
Finland	425
France	1,642
French Polynesia	14
Gabon	4
Georgia	79
Germany	2,947
Ghana	35
Gibraltar	8
Greece	1,369
Grenada	7
Guam	8
Guatemala	91
Guernsey	19
Guyana	8
Haiti	13
Honduras	18
Hong Kong	788
Hungary	526
Iceland	45

Country	#
India	16,177
Indonesia	1,199
Iran	250
Iraq	155
Ireland	2,483
Isle of Man	62
Israel	580
Italy	2,097
Jamaica	33
Japan	633
Jersey	15
Jordan	121
Kazakhstan	48
Kenya	161
Kosovo	59
Kuwait	102
Kyrgyzstan	12
Laos	12
Latvia	98
Lebanon	229
Libya	10
Lithuania	123
Luxembourg	39
Macao	20
Madagascar	4
Malawi	4
Malaysia	1,248
Maldives	27
Mali	16
Malta	127
Mauritius	65
Mexico	593

GRACE'S 2023 Global Reach

Country	#
Moldova	28
Monaco	48
Mongolia	10
Montenegro	50
Morocco	224
Myanmar (Burma)	59
Namibia	19
Nepal	144
Netherlands	1,950
New Zealand	1,076
Nicaragua	35
Nigeria	302
North Macedonia	187
Norway	509
Oman	33
Pakistan	1,094
Palestine	17
Panama	110
Papua New Guinea	37
Paraguay	9
Peru	2,347
Philippines	2,548
Poland	809
Portugal	357
Puerto Rico	158
Qatar	70
Romania	3,444
Russia	441
Rwanda	7
Saint Maarten	4
Saudi Arabia	459
Senegal	4

Country	#
Serbia	753
Singapore	1,841
Slovakia	313
Slovenia	506
Soloman Islands	3
Somalia	6
South Africa	638
South Korea	665
Spain	1,418
Sri Lanka	134
St. Kitts & Nevis	10
St. Lucia	8
Suriname	4
Sweden	758
Switzerland	580
Syria	16
Taiwan	571
Tanzania	7
Thailand	661
Trinidad & Tobago	99
Tunisia	62
Turkey	1,032
Turks & Caicos Islands	4
U.S. Virgin Islands	27
Uganda	94
Ukraine	532
United Arab Emirates	555
United Kingdom	33,734
Uruguay	797
Uzbekistan	29
Venezuela	54
Vietnam	630

Country	#
Yemen	28
Zambia	20
Zimbabwe	35

TOTAL REACH OUTSIDE THE UNITED STATES | 232,783